Literature DB >> 11278720

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin.

G E Stoica1, A Kuo, A Aigner, I Sunitha, B Souttou, C Malerczyk, D J Caughey, D Wen, A Karavanov, A T Riegel, A Wellstein.   

Abstract

Pleiotrophin (PTN) is a secreted growth factor that induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. During tumor growth PTN can serve as an angiogenic factor and drive tumor invasion and metastasis. To identify a receptor for PTN, we panned a phage display human cDNA library against immobilized PTN protein as a bait. From this we isolated a phage insert that was homologous to an amino acid sequence stretch in the extracellular domain (ECD) of the orphan receptor tyrosine kinase anaplastic lymphoma kinase (ALK). In parallel with PTN, ALK is highly expressed during perinatal development of the nervous system and down-modulated in the adult. Here we show in cell-free assays as well as in radioligand receptor binding studies in intact cells that PTN binds to the ALK ECD with an apparent Kd of 32 +/- 9 pm. This receptor binding is inhibited by an excess of PTN, by the ALK ECD, and by anti-PTN and anti-ECD antibodies. PTN added to ALK-expressing cells induces phosphorylation of both ALK and of the downstream effector molecules IRS-1, Shc, phospholipase C-gamma, and phosphatidylinositol 3-kinase. Furthermore, the growth stimulatory effect of PTN on different cell lines in culture coincides with the endogenous expression of ALK mRNA, and the effect of PTN is enhanced by ALK overexpression. From this we conclude that ALK is a receptor that transduces PTN-mediated signals and propose that the PTN-ALK axis can play a significant role during development and during disease processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278720     DOI: 10.1074/jbc.M010660200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  104 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 2.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

3.  Circulating IGF1 regulates hippocampal IGF1 levels and brain gene expression during adolescence.

Authors:  Han Yan; Matthew Mitschelen; Georgina V Bixler; Robert M Brucklacher; Julie A Farley; Song Han; Willard M Freeman; William E Sonntag
Journal:  J Endocrinol       Date:  2011-07-12       Impact factor: 4.286

4.  Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system.

Authors:  Shawn P Hurley; Douglas O Clary; Valerie Copie; Frances Lefcort
Journal:  J Comp Neurol       Date:  2006-03-10       Impact factor: 3.215

Review 5.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

6.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

Authors:  Marius Grzelinski; Florian Steinberg; Tobias Martens; Frank Czubayko; Katrin Lamszus; Achim Aigner
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 7.  Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Cancer J       Date:  2015 Sep-Oct       Impact factor: 3.360

Review 8.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

9.  Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Authors:  S E Gombash; F P Manfredsson; R J Mandel; T J Collier; D L Fischer; C J Kemp; N M Kuhn; S L Wohlgenant; S M Fleming; C E Sortwell
Journal:  Gene Ther       Date:  2014-05-08       Impact factor: 5.250

10.  Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Authors:  Analia Rodríguez Garzotto; C Vanesa Díaz-García; Alba Agudo-López; Elena Prieto García; Santiago Ponce; José A López-Martín; Luis Paz-Ares; Lara Iglesias; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.